Clinical Trials
FDA accepts protocols, endpoints for remaining phase 3 trials on PL9643 for dry eye
The FDA and Palatin Technologies have agreed on protocols and sign and symptom endpoints for the remaining phase 3 clinical trials of PL9643 for dry eye disease, the company announced in a press release.
Prescription digital therapeutic reduces monthly migraine days, phase 3 study shows
A novel digital therapeutic for migraine prevention met its primary endpoint of reducing the number of monthly migraine days, according to results from a phase 3 clinical trial.
Novel Duchenne therapy shows promise for halting disease progression
A combination therapy led to significant dystrophin expression and functional improvement in patients with Duchenne muscular dystrophy amenable to exon 51 skipping, according to new data from a phase 1/2 clinical trial.
Tolebrutinib delays onset of MS disability progression in phase 3 trial
An oral brain-penetrant therapeutic delayed the onset of confirmed disability progression compared with placebo in those with non-relapsing secondary progressive MS, according to results from a phase 3 study.
Phase 3 clinical trial commences for oral myasthenia gravis treatment
The first patient has been dosed in a phase 3 clinical trial of oral cladribine for the treatment of generalized myasthenia gravis, according to the manufacturer.
Small molecule oligomer antagonist for Alzheimer’s disease boosts brain connectivity
Results of an ongoing clinical trial showed that an oral, small molecule oligomer antagonist used to treat mild to moderate Alzheimer’s disease boosted connectivity between regions of the brain as a promising sign of cognitive improvement.
Platform designed to simplify process of matching, connecting patients to clinical trials
A health technology startup in the United Kingdom has developed an online platform designed to streamline the process through which patients are matched and connected to appropriate clinical trials.
FDA’s Oncology Center of Excellence initiative aims to expand clinical trial access
The FDA’s Oncology Center of Excellence has launched a public health initiative designed to improve access to clinical trials of oncology medical products for historically underrepresented populations.
Suvorexant acutely effective in reducing Alzheimer’s-related biomarkers
PHILADELPHIA — In cognitively healthy but sleep-poor adults in midlife, treatment with 20 mg suvorexin led to acute decreases in Alzheimer’s-related biomarkers compared with 10 mg of the drug and placebo, according to a presenter.
Leukemia & Lymphoma Society awards more than $2M to Fox Chase researchers
The Leukemia & Lymphoma Society awarded a research team at Fox Chase Cancer Center a nearly $2.4 million grant to improve clinical trial access for patients, particularly those from underrepresented groups, across the Temple Health system.